Allogene (ALLO) Form 144: 7,132 RSU Shares Notice

Allogene Therapeutics, Inc. reported a Form 144 notice for 7,132 shares of Common Stock tied to the vesting of a restricted stock unit award on 02/28/2026.

Rhea-AI Filing Summary

Allogene Therapeutics, Inc. reported a Form 144 notice for 7,132 shares of Common Stock tied to the vesting of a restricted stock unit award on 02/28/2026. The filing lists Morgan Stanley Smith Barney LLC as the broker and NASDAQ as the market.

Insights

Securities Counsel

Routine Form 144 notice for vested RSUs being registered for sale

Form 144 lists 7,132 shares of Common Stock associated with the vesting of a restricted stock unit award on 02/28/2026. The entry identifies Morgan Stanley Smith Barney LLC as the broker-dealer and NASDAQ as the market.

The filing is procedural: it notifies the broker and the market of an intended sale under Section 144. Timing, intended sale methods, and proceeds treatment are not specified in the excerpt; subsequent broker reports or trade confirmations would show execution details.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Allogene Therapeutics' Form 144 for ALLO mean?

It notifies the market of an intended sale of 7,132 shares tied to RSU vesting on 02/28/2026. The filing names Morgan Stanley Smith Barney LLC as the broker and lists NASDAQ as the market.

Who is the broker listed on the ALLO Form 144?

The broker-dealer listed is Morgan Stanley Smith Barney LLC with an address at 1 New York Plaza, New York. The filing connects the broker to the proposed handling of 7,132 shares.

What security and event triggered the Form 144 for ALLO?

The security is Common Stock, and the triggering event is the vesting of a restricted stock unit award dated 02/28/2026, with 7,132 shares shown in the notice.

Does the Form 144 state how the shares will be sold?

The excerpt lists broker and market but does not describe sale methods or proceeds. It shows 7,132 shares related to RSU vesting on 02/28/2026; execution details are not provided here.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 09:04 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002057918
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Allogene Therapeutics, Inc.
SEC File Number	001-38693
Address of Issuer	210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CALIFORNIA 94080
Phone	(650) 457-2700
Name of Person for Whose Account the Securities are To Be Sold	Beneski Benjamin Machinas
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	7132	18541.16	224730144	03/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/28/2026	Vesting of restricted stock unit award	Allogene Therapeutics, Inc			7132	02/28/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	03/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	BENJAMIN MACHINAS BENESKI
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)